These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 11195538

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Growth hormone and prolactin stimulation by Madopar in Parkinson's disease.
    Martinez-Campos A, Giovannini P, Parati E, Novelli A, Caraceni T, Müller EE.
    J Neurol Neurosurg Psychiatry; 1981 Dec; 44(12):1116-23. PubMed ID: 7334406
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
    Crevoisier C, Monreal A, Metzger B, Nilsen T.
    Eur Neurol; 2003 Dec; 49(1):39-44. PubMed ID: 12464717
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Comparison of subcutaneous apomorphine versus dispersible madopar latency and effect duration in Parkinson's disease patients: a double-blind single-dose study.
    Merello M, Pikielny R, Cammarota A, Leiguarda R.
    Clin Neuropharmacol; 1997 Apr; 20(2):165-7. PubMed ID: 9099469
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Concentration-effect relationship of levodopa-benserazide dispersible formulation versus standard form in the treatment of complicated motor response fluctuations in Parkinson's disease.
    Contin M, Riva R, Martinelli P, Cortelli P, Albani F, Baruzzi A.
    Clin Neuropharmacol; 1999 Apr; 22(6):351-5. PubMed ID: 10626097
    [Abstract] [Full Text] [Related]

  • 34. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R, Koller WC.
    Adv Neurol; 1996 Apr; 69():487-91. PubMed ID: 8615169
    [No Abstract] [Full Text] [Related]

  • 35. The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off" periods in Parkinson's disease.
    Steiger MJ, Stocchi F, Carta A, Ruggieri S, Agnoli A, Quinn NP, Marsden CD.
    Clin Neuropharmacol; 1991 Jun; 14(3):241-4. PubMed ID: 2070364
    [Abstract] [Full Text] [Related]

  • 36. A controlled release form of madopar in parkinsonian patients with advanced disease and marked fluctuations in motor performance.
    Jensen NO, Dupont E, Hansen E, Mikkelsen B, Mikkelsen BO.
    Acta Neurol Scand; 1988 May; 77(5):422-5. PubMed ID: 3046226
    [Abstract] [Full Text] [Related]

  • 37. Madopar HBS and the decompensated phase of Parkinson disease.
    Caraceni T, Nordera N, Lamperti E, Lorizio A.
    Ital J Neurol Sci; 1989 Aug; 10(4):407-14. PubMed ID: 2793413
    [Abstract] [Full Text] [Related]

  • 38. [Levodopa and controlled release benserazide in the handling of motor fluctuations in Parkinson's disease].
    Díaz F, Chaná P.
    Rev Med Chil; 1991 Sep; 119(9):1022-8. PubMed ID: 1845094
    [Abstract] [Full Text] [Related]

  • 39. [Idiopathic Parkinson's disease: practical hints for the treatment].
    Ludin HP.
    Praxis (Bern 1994); 2005 Jul 27; 94(30-31):1147-50. PubMed ID: 16117469
    [Abstract] [Full Text] [Related]

  • 40. A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease.
    MacMahon DG, Sachdev D, Boddie HG, Ellis CJ, Kendal BR, Blackburn NA.
    J Neurol Neurosurg Psychiatry; 1990 Mar 27; 53(3):220-3. PubMed ID: 2182781
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.